drugset / Trial / NCT04532229
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).
Timeline
- Start
- 2021-04-03
- Primary completion
- 2023-10-08
- Completion
- 2023-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 150 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |